Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...

A federal judge refused to allow drug compounders to keep making copycats of Novo Nordisk A/S’s weight loss drug while a ...

Victoza is Novo Nordisk’s once-daily injectable GLP-1 agonist and made around $3.6 billion in sales last year, making it the top-selling drug in the category.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk’s strong intangible assets in diabetes ... and biosimilar insulins have weighed on category pricing since 2017. Novo’s Victoza and Ozempic have made GLP-1 a key part of the ...

Novo Nordisk A/S slumped amid concern that a weight-loss pill from rival Eli Lilly & Co. will steal market share from bestsellers such as its injected blockbuster Ozempic. The stock dropped as ...

Let's continue. Novo Nordisk's semaglutide franchise consists of Ozempic, Rybelsus, and Victoza, whose sales totaled about DKK 40.77 billion in the last three months of 2024, up 15.6% quarter-on ...